COMPASS Pathways plc
CMPSNasdaq
$12.35
↓ -0.6%Jul 17 close · end-of-day
Price
1Y↑ +214.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.6B
Enterprise Value
$1.2B
P/E
—
P/S
—
P/B
4.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$160.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-49.2%
ROIC
—
Debt / Equity
0.2
Net Cash
$415.5M
Return 1Y
+218.3%
Company profile
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression. The company was formerly known as COMPASS Rx Limited.
- CEO
- Kabir K. Nath
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Website
- compasspathways.com
Management & directors
- Loxam TeriChief Financial Officer
- Nath KabirChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
CMPS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.30↑ +25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$51.4M | -$83.2M | -$110.4M | -$136.9M | -$178.2M | -$179.0M |
| Net income | -$60.3M | -$71.7M | -$91.5M | -$118.5M | -$155.1M | -$269.8M |
| Diluted EPS | -$3.55 | -$1.79 | -$2.16 | -$2.32 | -$2.30 | -$3.08 |
| Operating cash flow | -$41.4M | -$67.7M | -$105.5M | -$97.4M | -$119.2M | -$157.2M |
| Free cash flow | -$41.5M | -$68.1M | -$106.0M | -$97.4M | -$119.2M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$43.3M | -$47.9M | -$48.4M | -$49.6M | -$42.9M | -$40.5M | -$46.0M | -$42.9M |
| Net income | -$38.1M | -$38.5M | -$43.3M | -$17.9M | -$38.4M | -$137.7M | -$75.8M | $91.2M |
| Diluted EPS | -$0.56 | -$0.56 | -$0.63 | -$0.24 | -$0.41 | -$1.44 | -$0.99 | -$0.30 |
| Operating cash flow | -$34.4M | -$22.2M | -$41.8M | -$45.7M | -$38.7M | -$35.1M | -$37.8M | -$47.9M |
| Free cash flow | -$34.4M | -$22.2M | -$41.8M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 17, 2026
- 3d agoCompass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapyproactiveinvestors.com
- 3d agoEuropean Equities Traded in the US as American Depositary Receipts Decline Fridayfinance.yahoo.com
- 3d agoCOMPASS Pathways (CMPS) Is Down 8.6% After Phase 3 Durability Data For COMP360 In TRDfinance.yahoo.com
Jul 16, 2026
- 3d agoStock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billionfool.com
- 4d agoEuropean Equities Traded in the US as American Depositary Receipts Edge Lower Thursdayfinance.yahoo.com
- 4d agoWhy Psychedelic stocks are surging todayfinance.yahoo.com
- 4d agoATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?stocktwits.com
- 4d agoCompass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapyfinance.yahoo.com
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-26 | Nath Kabir· Chief Executive Officer | Award | 175,000 | $0.00 | $0.00 | filing |
| 2026-03-26 | Loxam Teri· Chief Financial Officer | Award | 75,000 | $0.00 | $0.00 | filing |
| 2026-03-11 | Nath Kabir· Chief Executive Officer | Tax withholding | 13,131 | $6.89 | $90,472.59 | filing |
| 2026-03-11 | Loxam Teri· Chief Financial Officer | Tax withholding | 1,781 | $6.89 | $12,271.09 | filing |
| 2026-03-02 | Loxam Teri· Chief Financial Officer | Tax withholding | 4,467 | $7.02 | $31,358.34 | filing |
| 2026-02-02 | Nath Kabir· Chief Executive Officer | Tax withholding | 16,181 | $6.61 | $106,956.41 | filing |
| 2025-08-01 | Nath Kabir· Chief Executive Officer | Tax withholding | 6,366 | $4.34 | $27,628.44 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.